GlassScriptPhysician profile
Alyssa M Smith
NPI 1407321680
$5,359.58
in general payments reported to CMS, 2019-2025
35 companies · $777 in 2025
The $777 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $826 · 2022: $1,699 · 2023: $1,083 · 2024: $975 · 2025: $777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,095.36 | 2021-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $466.77 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $457.69 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.29 | 2021-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $384.52 | 2021-2024 | |
| Corcept Therapeutics | $382.27 | 2022-2025 | Korlym |
| Merck Sharp & Dohme LLC | $342.95 | 2021-2025 | Capvaxive |
| Xeris Pharmaceuticals, INC. | $212.91 | 2021-2025 | Gvoke Hypopen |
| Abbvie INC. | $192.53 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $168.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $166.61 | 2023-2025 | |
| Glaxosmithkline, LLC. | $112.53 | 2023-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $111.26 | 2021-2024 | Veozah |
| Viiv Healthcare Company | $77.39 | 2024-2025 | Apretude, Dovato |
| Boston Scientific Corporation | $76.38 | 2025 | General - Pain Management |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $72.90 | 2021-2025 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $63.70 | 2022-2025 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $51.99 | 2021 | |
| Pfizer INC. | $51.54 | 2021-2024 | |
| Lifescan, INC. | $46.95 | 2021-2022 | |
| Daiichi Sankyo INC. | $42.61 | 2021 | |
| Lucid Diagnostics INC. | $42.56 | 2022 | |
| Ascensia Diabetes Care US INC. | $39.66 | 2023-2024 | |
| Globus Medical, INC. | $31.77 | 2025 | Senza |
| Amarin Pharma, INC. | $30.43 | 2021 | |
| Esperion Therapeutics, INC. | $23.18 | 2021 | |
| Janssen Biotech, INC. | $22.04 | 2023 | Symtuza |
| La Jolla Pharmaceutical Company | $21.32 | 2023 | Xerava |
| Edwards Lifesciences Corporation | $20.38 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Actelion Pharmaceuticals US, INC. | $19.72 | 2024 | Opsumit |
| Kyowa Kirin, INC. | $19.37 | 2023 | Crysvita |
| Biohaven Pharmaceuticals, INC. | $18.96 | 2021 | |
| Inspire Medical Systems, INC. | $15.09 | 2024 | Inspire |
| Cumberland Pharmaceuticals, INC. | $14.40 | 2024 | Vibativ |
| Medtronic, INC. | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.